Number;Cell Line;Vector Name;Vector no.;Label (if divergent to col.1&2) /Clone no.;Date of Freezing;Frozen by;Additional Information1;"U937 458 ""normal""";pMIAII;85;;40735;KS;"frisch gesortet! myco-; Infektion von KS am 4.7.2011"2;"U937 53 ""normal""";pMIAII;85;;41239;SK;2nd freeze, first freeze (11.07.11 by KS)3;"U937 53 ""normal""";pMIAII;85;;41239;SK;2nd freeze, first freeze (11.07.11 by KS)4;"U937 458 ""normal""";pMIAII p21-cDNA;558;;40722;KS;"gesortet; alle positiv ,myco-"5;"U937 458 ""normal""";pMIAII p21-cDNA;558;;40722;KS;"gesortet; alle positiv ,myco-"6;"U937 458 ""normal""";pMIAII p21-cDNA;558;;40722;KS;"gesortet; alle positiv ,myco-"7;U937;pBMN-IRES-eGFP;53;;41499;JET;cultured 15.07.13 - 13.08.138;U937;pBMN-IRES-eGFP;53;;41499;JET;cultured 15.07.13 - 13.08.139;"U937 53 ""normal""";pMIAII;85;;40722;KS;"gesortet; alle positiv; myco-"10;"U937 53 ""normal""";pMIAII p21-cDNA;558;;40722;KS;"gesortet; alle positiv ,myco-"11;"U937 53 ""normal""";pMIAII p21-cDNA;558;;40722;KS;"gesortet; alle positiv ,myco-"12;"U937 53 ""normal""";pMIAII p21-cDNA;558;;40722;KS;"gesortet; alle positiv ,myco-"13;"U937 53 ""normal""";pMIAII p21-cDNA;558;;40711;AR;SORT, 46,1% positive ,myco-14;"U937 53 ""normal""";pMIAII p21-cDNA;558;;40711;AR;SORT, 46,1% positive ,myco-15;"U937 458 ""normal""";pMIAII p21-cDNA;558;;40711;AR;SORT, 69,4% positive ,myco-16;"U937 458 ""normal""";pMIAII p21-cDNA;558;;40711;AR;SORT, 69,4% positive ,myco-17;"U937 458 ""normal""";pMIAII;85;;41239;SK;2nd freeze, first freeze (28.06.11 by KS)18;"U937 458 ""normal""";pMIAII;85;;41239;SK;2nd freeze, first freeze (28.06.11 by KS)19;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40716;KS; ,myco-20;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40716;KS; ,myco-21;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40716;KS; ,myco-22;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40716;KS; ,myco-23;"U937 458 ""normal""";pMIA II MS4A3-cDNA;556;;40716;KS; ,myco-24;"U937 458 ""normal""";pMIA II MS4A3-cDNA;556;;40716;KS; ,myco-25;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40711;KS;1. freeze nach AR Infektion von U937 53 mit 556, myco-26;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40711;KS;1. freeze nach AR Infektion von U937 53 mit 556, myco-27;"U937 53 ""normal""";pMIA II MS4A3-cDNA;556;;40711;KS;1. freeze nach AR Infektion von U937 53 mit 556, myco-28;"U937 458 ""normal""";pMIA II MS4A3-cDNA;556;;40711;KS;1. freeze nach AR Infektion von U937 458 mit 556, myco-29;"U937 458 ""normal""";pMIA II MS4A3-cDNA;556;;40711;KS;1. freeze nach AR Infektion von U937 458 mit 556, myco-30;"U937 458 ""normal""";pMIA II MS4A3-cDNA;556;;40711;KS;1. freeze nach AR Infektion von U937 458 mit 556, myco-31;U937;pBMN-IRES-eGFP EVI1;458;;41499;JET;cultured 15.07.13 - 13.08.1332;U937;pBMN-IRES-eGFP EVI1;458;;41499;JET;cultured 15.07.13 - 13.08.1333;U937;pBMN-IRES-eGFP EVI1;458;;41499;JET;cultured 15.07.13 - 13.08.1334;U937;pBMN-IRES-eGFP EVI1;458;;40147;AK; all weak GFP+, later vial was tested myco-35;U937;pBMN-IRES-eGFP EVI1;458;;40108;AK;1.Sort (all weak GFP+, 5.5% ++) later vial was tested myco-36;U937;pBMN-IRES-eGFP EVI1;458;;40126;AK;2.Sort GFP++ later vial was tested myco-37;U937;pBMN-IRES-eGFP EVI1;458;;40126;AK;2.Sort GFP++ later vial was tested myco-38;U937;pBMN-IRES-eGFP EVI1;458;;40126;AK;2.Sort GFP low (still EVI1 expressing) later vial was tested myco-39;U937;pBMN-IRES-eGFP EVI1;458;;40126;AK;2.Sort GFP low (still EVI1 expressing) later vial was tested myco-40;U937;pBMN-IRES-eGFP EVI1;458;;40126;AK;100% weak GFP+ later vial was tested myco-41;U937;pBMN-IRES-eGFP EVI1;458;;40126;AK;100% weak GFP+ later vial was tested myco-42;U937;pBMN-IRES-eGFP EVI1;458;;40540;AR;Working Stock,  parallel freeze tested mycoplasm free43;U937;pBMN-IRES-eGFP;53;;40141;AK;later vial was tested myco-44;U937;pBMN-IRES-eGFP;53;;40141;AK;later vial was tested myco-45;U937;pBMN-IRES-eGFP;53;;41488;KS;" von den ersten freezes vom 24.11.09 von Anna Rommer; (later vial was tested myco-)"46;U937;pBMN-IRES-eGFP;53;;41488;KS;" von den ersten freezes vom 24.11.09 von Anna Rommer; (later vial was tested myco-)"47;;;;;;;48;U937;pBMN-IRES-eGFP EVI1;458;;40154;AK;Working Stock,  parallel freeze tested mycoplasm free49;U937;pBMN-IRES-eGFP EVI1;458;;41488;KS; vom Working Stock Anna vom 7.12.09,  parallel freeze tested mycoplasm free50;U937;pBMN-IRES-eGFP EVI1;458;;41488;KS; vom Working Stock Anna vom 7.12.09,  parallel freeze tested mycoplasm free51;;;;;;;52;U937;pBMN-IRES-eGFP EVI1;458;;40134;AK;2.Sort GFP low (still EVI1 expressing) later vial was tested myco-53;U937;pBMN-IRES-eGFP EVI1;458;;40134;AK;2.Sort GFP low later vial was tested myco-54;U937;pBMN-IRES-eGFP;53;;40290;CN;1.Sort, U937 Cerny Lab, Phoenix from Stockinger Lab55;U937 458;pMIA II MS4A3-cDNA/pMSCV-eGFP MS4A3short;556/591;;41494;JET;"Sort vom 29.7.13; zweiter freeze; myco-"56;U937 458;pMIA II MS4A3-cDNA/pMSCV-eGFP MS4A3short;556/591;;41494;JET;"Sort vom 29.7.13; zweiter freeze; myco-"57;U937 458;pMIA II MS4A3-cDNA/pMSCV-eGFP MS4A3short;556/591;;41494;JET;"Sort vom 29.7.13; zweiter freeze; myco-"58;U937 458;pMIAII/pMSCV-eGFP;85/74;;41494;JET;"Sort vom 29.7.13; zweiter freeze; myco-"59;U937 458;pMIAII/pMSCV-eGFP;85/74;;41494;JET;"Sort vom 29.7.13; zweiter freeze; myco-"60;U937 458;pMIAII/pMSCV-eGFP;85/74;;41494;JET;"Sort vom 29.7.13; zweiter freeze; myco-"61;U937;pBMN-IRES-eGFP;53;U937 53-2;40228;AK;Infection Lina (second set of U937-53 cells) CAVE: no differentation with TPA,  parallel freeze tested mycoplasm free62;U937;pBMN-IRES-eGFP;53;U937 53-2;40228;AK;Infection Lina (second set of U937-53 cells) CAVE: no differentation with TPA,  parallel freeze tested mycoplasm free63;U937;pBMN-IRES-eGFP;53;U937 53-2;40228;AK;Infection Lina (second set of U937-53 cells) CAVE: no differentation with TPA,  parallel freeze tested mycoplasm free64;U937;pBMN-IRES-eGFP;53;U937 53-2;40228;AK;Infection Lina (second set of U937-53 cells) CAVE: no differentation with TPA,  parallel freeze tested mycoplasm free65;U937;pBMN-IRES-eGFP;53;U937 53-2;40228;AK;Infection Lina (second set of U937-53 cells) CAVE: no differentation with TPA,  parallel freeze tested mycoplasm free66;U937eco;pBMN-IRES-eGFP;53;;40290;CN;1.Sort67;U937eco;;53;;40401;IA;sorted twice, 100%GFP+68;U937eco;PBMN-IRES-eGFP EVI1;458;;40290;CN;1.Sort69;U937eco;;458;;40401;IA;sorted twice, 100%GFP+70;U937;pBMN-IRES-eGFP;53;U937-pBMN;40263;BSt;Infectin Lina (second set of U937-53 cells), 2nd sort, myco-free71;U937;pBMN-IRES-eGFP;53;U937-pBMN;40263;BSt;Infectin Lina (second set of U937-53 cells), 2nd sort, myco-free72;U937;pBMN-IRES-eGFP;53;U937-pBMN;40263;BSt;Infectin Lina (second set of U937-53 cells), 2nd sort, myco-free73;U937;PBMN-IRES-eGFP EVI1;458;U937-pBMN-EVI1;40277;BSt;Infection Lina (second set of U937-458 cells) 2nd sort(only 1.8% positive), mykokill treated74;U937;PBMN-IRES-eGFP EVI1;458;U937-pBMN-EVI1;40277;BSt;Infection Lina (second set of U937-458 cells) 2nd sort(only 1.8% positive), mykokill treated75;U937;PBMN-IRES-eGFP EVI1;458;U937-pBMN-EVI1;40277;BSt;Infection Lina (second set of U937-458 cells) 2nd sort(only 1.8% positive), mykokill treated76;U937;pBMN-IRES-eGFP;53;U937-pBMN;40277;BSt;Infectin Lina (second set of U937-53 cells), 2nd sort, myco-free77;U937;pBMN-IRES-eGFP;53;U937-pBMN;40277;BSt;Infectin Lina (second set of U937-53 cells), 2nd sort, myco-free78;U937;pBMN-IRES-eGFP;53;U937-pBMN;40277;BSt;Infectin Lina (second set of U937-53 cells), 2nd sort, myco-free79;;;;;;;80;;;;;;;81;;;;;;;